A trained scent dog was able to accurately identify thyroid cancer in urine samples from patients with thyroid nodules.
Sunitinib appears to exhibit significant antitumor activity in patients with advanced differentiated thyroid cancer.
After 5 years, less than 1% of asymptomatic nodules studied were diagnosed as thyroid cancer.
Drug approved to treat progressive, differentiated thyroid cancer that is refractory to radioactive iodine therapy.
Lenvatinib improved progression-free survival and response rate in I-131-refractory thyroid cancer.
Richard T. Kloos, MD, discusses new technologies and methods for diagnosis of thyroid nodules.
Radioactive iodine therapy was associated with improved survival and reduced mortality risk.
Radiation effects on thyroid nodules were noted in people who survived the atomic bombings at Hiroshima and Nagasaki.
Kenneth D. Burman, MD, discusses one study suggesting that the optimal time for repeat evaluation of benign thyroid nodules is 2 to 4 years.